Primary percutaneous stenting for palliative biliary drainage of patients with malignant hilar biliary obstruction: TESLA trial [0.03%]
经皮肝穿刺胆道造影引流支架植入术治疗恶性肝门部胆管梗阻患者：TESLA试验
Stijn Franssen,Merve Rousian,Victorien van Verschuer et al.
Stijn Franssen et al.
Background & aims: Palliative patients with malignant hilar biliary obstruction typically undergo endoscopic or internal/external percutaneous biliary drainage. Both approaches may cause bacterial colonization of the bile...
Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing [0.03%]
通过全外显子组、转录组和单细胞测序揭示与病毒相关的肝癌中T细胞耗竭异质性和HBV整合的景观分布状况
Soon Kyu Lee,Jinyeong Lim,Joo Yeon Jhun et al.
Soon Kyu Lee et al.
Background & aims: To enhance our understanding of the tumor immune microenvironment (TIME) in hepatocellular carcinoma (HCC), we investigated the heterogeneity of T-cell exhaustion and its association with HBV integratio...
Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial [0.03%]
佩米拉肽治疗代谢功能障碍相关非酒精性脂肪性肝病的疗效和安全性：一项随机对照试验
Sarah K Browne,John J Suschak,Shaheen Tomah et al.
Sarah K Browne et al.
Background & aims: This was a double-blind 12-week extension of a randomized, placebo-controlled, 12-week trial of pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, in individuals with metabolic dysfu...
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis [0.03%]
持续性转氨酶正常的自身免疫性肝炎患者中孤立性的IgG升高不影响预后
Álvaro Díaz-González,Ida Schregel,Lorena Carballo et al.
Álvaro Díaz-González et al.
Background & aims: The goal of treatment for autoimmune hepatitis is to achieve a complete biochemical response, defined as normalization of transaminases and immunoglobulin G (IgG) levels. Recent data suggest that IgG no...
Stine Johansen,Maja Thiele,Aleksander Krag
Stine Johansen
Metabolic- and alcohol-related liver disease (MetALD) and alcohol-related liver disease (ALD) are major drivers of the global burden of cirrhosis. While metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one-thi...
Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors [0.03%]
免疫治疗或酪氨酸激酶抑制剂治疗肝癌患者的疾病时间负担模式不同
Rex Wan-Hin Hui,Matthew Shing-Hin Chung,Lu Li et al.
Rex Wan-Hin Hui et al.
Background & aims: While cancer survivorship for hepatocellular carcinoma (HCC) has improved, associated disease time burden in patients taking systemic therapies remains poorly understood. In this study, we used days at ...
Real-world work productivity is impaired in people with metabolic dysfunction-associated steatotic liver disease in the USA [0.03%]
美国患有代谢紊乱相关肝脂肪病变的患者工作效率受损
Shraddha Shinde,Mary E Rinella,Mark L Hartman et al.
Shraddha Shinde et al.
Background & aims: The impact of metabolic dysfunction-associated steatohepatitis (MASH) on patient-reported outcomes is poorly understood. We assessed work productivity burden in a real-world population with suspected/co...
The 'social gradient' in primary liver cancer in France: A national observational study [0.03%]
法国肝癌的社会阶层差异：一项全国观察性研究
Marie Strigalev,David Fuks,Sandrine Katsahian et al.
Marie Strigalev et al.
Background & aims: Social deprivation has been associated with primary liver cancer (PLC); however, its impact on access to curative treatment and survival remains uncertain. We assessed the effect of deprivation on healt...
Epidemiology, comorbidities, treatments and outcomes of autoimmune liver diseases: A French nationwide study [0.03%]
自身免疫性肝病的流行病学、共病、治疗和结果：一项法国全国性研究
Christophe Corpechot,Pierre Hornus,Mallory Cals et al.
Christophe Corpechot et al.
Background & aims: The epidemiology, clinical management, and prognosis of autoimmune liver diseases (AILDs) - including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (P...
Barbara Bueloni,Esteban Fiore,María José Cantero et al.
Barbara Bueloni et al.
Background & aims: The Rho GTPase RAC1 regulates key processes in acute liver failure (ALF), including oxidative stress and inflammation. We aimed to evaluate the therapeutic potential of RAC1 inhibition in ALF. ...